Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated
